[EN] [1, 2, 4] TRIAZOLO [1, 5-A] PYRIDINES AS JAK INHIBITORS<br/>[FR] [1, 2, 4]TRIAZOLO[1, 5-A]PYRIDINES UTILISÉES COMME INHIBITEURS DE JAK
申请人:GALAPAGOS NV
公开号:WO2010010184A1
公开(公告)日:2010-01-28
Novel [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a Formula represented by the following: (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, joint disease, inflammation, and others.
Synthesis of functionalised 4H-quinolizin-4-ones via tandem Horner–Wadsworth–Emmons olefination/cyclisation
作者:Calum W. Muir、Alan R. Kennedy、Joanna M. Redmond、Allan J. B. Watson
DOI:10.1039/c3ob40578h
日期:——
4H-Quinolizin-4-ones are a unique class of heterocycle with valuable physicochemical properties and which are emerging as key pharmacophores for a range of biological targets. A tandem HornerâWadsworthâEmmons olefination/cyclisation method has been developed to allow facile access to substituted 4H-quinolizin-4-ones encoded with a range of functional groups.
Fluorescence emission properties in single molecule, crystalline and amorphous state are key factors determining the application fields and scope of luminogens. However, the luminescenceefficiency of luminogens are usually inconsistent under three existence forms. To explore multi-state emission properties and the inherent mechanism of luminogens, and obtain rare mechanical force-induced luminescent
The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit hi-stone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.